Project Grant R01CA285439
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$472K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This federal Project Grant award of $399,129 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University aims to develop a novel treatment strategy for triple-negative breast cancer (TNBC). The research will investigate combining a DDX3 inhibitor (RK-33) to alter the tumor's metabolic environment with immunotherapy to generate an effective and sustained immune response against TNBC. Specifically, the grant will fund research under three key...
This federal Project Grant award of $781,436 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Cold Spring Harbor Laboratory (CSHL) to optimize anti-N-methyl-D-aspartate receptor (NMDAR) antibodies for the treatment of triple-negative breast cancer (TNBC). The key goals are to: 1) establish an orthotopic mouse model with inducible NMDAR expression in TNBC tumors, 2) screen for NMDAR-reactive antibodies and use cryo-electron microscopy to identify...
This federal Project Grant award of $590,625 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, Davis (UC Davis) to develop a novel therapeutic strategy targeting mutant p53 in triple negative breast cancers (TNBCs). The key objectives are to: 1) determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and the role of mutant p53 as a target of CDK4/6 inhibitors to suppress...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $631,492 to The University of Kentucky Research Foundation to conduct research aimed at identifying nicotinamide N-methyltransferase (NNMT) as a new target for treating triple-negative breast cancer (TNBC). The key goals are to define how NNMT promotes anchorage-independent growth and protects TNBC cells from ferroptosis, evaluate the efficacy of a newly developed NNMT bisubstrate...
The National Cancer Institute (NCI) awarded Virginia Commonwealth University (VCU) a $1,241,427 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a small molecule inhibitor called PDZ1I for treating advanced, metastatic triple negative breast cancer (TNBC). The project aims to formulate PDZ1I-nano for clinical use, characterize how it stimulates the immune system to suppress tumor growth, define the signaling pathways it targets, and combine it...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This federal Project Grant award, valued at $616,071 and effective from February 2025 to January 2030, was granted by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The University of Texas Health Science Center at San Antonio (UTHSCSA). The grant supports the development of novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). TNBC accounts for 15-20% of the approximately 280,000 annual breast cancer diagnoses in...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $619,764 to the University of Wisconsin - Madison to develop new combination immunotherapy strategies for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor (P-aPDL1) by triggering local thrombus formation in TNBC tumors, and 2) modulate the immunosuppressive...
This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...